MDCO - The Medicines Company: Limited Upside And A Tough Market Battle For Inclisiran

I took interest in The Medicines Company (MDCO) as part of my research on Alnylam (ALNY), a potential Long-Term Growth Portfolio holding which has an economic interest in MDCO’s main asset inclisiran. The company is about to report inclisiran’s phase 3 topline results and while I think efficacy is pretty-much de-risked, safety still seems a risk and another important question is inclisiran’s market potential – inclisiran should be a more convenient therapy but it will enter a market with a lag of several years to Repatha and Praluent and it will